|
1
|
Hayden B, Jockovich ME, Murray TG,
Kralinger MT, Voigt M, Hernandez E, Feuer W and Parel JM:
Iontophoretic delivery of carboplatin in a murine model of
retinoblastoma. Invest Ophthalmol Vis Sci. 47:3717–3721. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Castillo BV Jr and Kaufman L: Pediatric
tumors of the eye and orbit. Pediatr Clin North Am. 50:149–172.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wiman KG: The retinoblastoma gene: Role in
cell cycle control and cell differentiation. FASEB J. 7:841–845.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
MacCarthy A, Birch JM, Draper GJ,
Hungerford JL, Kingston JE, Kroll ME, Onadim Z, Stiller CA, Vincent
TJ and Murphy MF: Retinoblastoma in Great Britain 1963-2002. Br J
Ophthalmol. 93:33–37. 2009. View Article : Google Scholar
|
|
5
|
Shields CL, Mashayekhi A, Au AK, Czyz C,
Leahey A, Meadows AT and Shields JA: The International
Classification of Retinoblastoma predicts chemoreduction success.
Ophthalmology. 113:2276–2280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abramson DH, Lawrence SD, Beaverson KL,
Lee TC, Rollins IS and Dunkel IJ: Systemic carboplatin for
retinoblastoma: Change in tumour size over time. Br J Ophthalmol.
89:1616–1619. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yanık Ö, Gündüz K, Yavuz K, Taçyıldız N
and Ünal E: Chemotherapy in retinoblastoma: Current approaches.
Turk J Ophthalmol. 45:259–267. 2015. View Article : Google Scholar
|
|
8
|
Smith SJ, Smith BD and Mohney BG: Ocular
side effects following intravitreal injection therapy for
retinoblastoma: A systematic review. Br J Ophthalmol. 98:292–297.
2014. View Article : Google Scholar
|
|
9
|
Winter U, Buitrago E, Mena HA, Del Sole
MJ, Laurent V, Negrotto S, Francis J, Arana E, Sgroi M and Croxatto
JO: et a l: Pharmacokinetics, safety, and efficacy of intravitreal
digoxin in preclinical models for retinoblastoma. Invest Ophthalmol
Vis Sci. 56:4382–4393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McKeage MJ: Lobaplatin: A new antitumour
platinum drug. Expert Opin Investig Drugs. 10:119–128. 2001.
View Article : Google Scholar
|
|
11
|
Shan L, Bai B, Lv Y, Xie B, Huang X and
Zhu H: Lobaplatin suppresses proliferation and peritoneal
metastasis of colorectal cancer in a preclinical model. Biomed
Pharmacother. 108:486–491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin CY, Lin XL, Tian L, Ye M, Yang XY and
Xiao XY: Lobaplatin inhibits growth of gastric cancer cells by
inducing apoptosis. World J Gastroenterol. 20:17426–17433. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie CY, Xu YP, Jin W and Lou LG: Antitumor
activity of lobaplatin alone or in combination with antitubulin
agents in non-small-cell lung cancer. Anticancer Drugs. 23:698–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen L, Cao H, Yu C and Feng Y: Lobaplatin
inhibits prostate cancer progression in part by impairing AR and
ERG signal. Fundam Clin Pharmacol. 32:548–557. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wheate NJ, Walker S, Craig GE and Oun R:
The status of platinum anticancer drugs in the clinic and in
clinical trials. Dalton Trans. 39:8113–8127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Q, Cheng Y, Huang L, Bai Y, Liang J
and Li X: Inhibitory effect of carboplatin in combination with
bevacizumab on human retinoblastoma in an in vitro and in vivo
model. Oncol Lett. 14:5326–5332. 2017.PubMed/NCBI
|
|
17
|
Gombos DS, Hungerford J, Abramson DH,
Kingston J, Chantada G, Dunkel IJ, Antoneli CB, Greenwald M, Haik
BG, Leal CA, et al: Secondary acute myelogenous leukemia in
patients with retinoblastoma: Is chemotherapy a factor?
Ophthalmology. 114:1378–1383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Moisan F, Francisco EB, Brozovic A, Duran
GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P and
Sikic BI: Enhancement of paclitaxel and carboplatin therapies by
CCL2 blockade in ovarian cancers. Mol Oncol. 8:1231–1239. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang H, Liu HZ, Wang HB, Zhong JY, Yang
CX and Zhang B: Dexmedetomidine protects against cisplatin induced
acute kidney injury in mice through regulating apoptosis and
inflammation. Inflamm Res. 66:399–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tamboli A, Podgor MJ and Horm JW: The
incidence of retinoblastoma in the United States 1974 through 1985.
Arch Ophthalmol. 108:128–132. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim DY, Choi JA, Koh JY and Yoon YH:
Efficacy and safety of aflibercept in in vitro and in vivo models
of retinoblastoma. J Exp Clin Cancer Res. 35:1712016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balmer A, Zografos L and Munier F:
Diagnosis and current management of retinoblastoma. Oncogene.
25:5341–5349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dilruba S and Kalayda GV: Platinum-based
drugs: Past, present and future. Cancer Chemother Pharmacol.
77:1103–1124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buckingham R, Fitt J and Sitzia J:
Patients' experiences of chemotherapy: Side-effects of carboplatin
in the treatment of carcinoma of the ovary. Eur J Cancer Care
(Engl). 6:59–71. 1997. View Article : Google Scholar
|
|
26
|
Kooijmans EC, Bökenkamp A, Tjahjadi NS,
Tettero JM, van Dulmen-den Broeder E, van der Pal HJ and Veening
MA: Early and late adverse renal effects after potentially
nephrotoxic treatment for childhood cancer. Cochrane Database Syst
Rev. 3:CD0089442019.PubMed/NCBI
|
|
27
|
Zhang H, Chen R, Wang X, Zhang H, Zhu X
and Chen J: Lobaplatin-induced apoptosis requires p53-mediated
p38MAPK activation through ROS generation in non-small-cell lung
cancer. Front Oncol. 9:5382019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Y, Xu XY, Yan F, Sun WL, Zhang Y, Liu
DL and Shen B: Retrospective study of the efficacy and toxicity of
lobaplatin in combined chemotherapy for metastatic breast cancer.
OncoTargets Ther. 12:4849–4857. 2019. View Article : Google Scholar
|
|
29
|
Du L, Fei Z, Song S and Wei N: Antitumor
activity of lobaplatin against esophageal squamous cell carcinoma
through caspase dependent apoptosis and increasing the Bax/Bcl 2
ratio. Biomed Pharmacother. 95:447–452. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hua S, Kong X, Chen B, Zhuang W, Sun Q,
Yang W, Liu W and Zhang Y: Anticancer mechanism of lobaplatin as
monotherapy and in combination with paclitaxel in human gastric
cancer. Curr Mol Pharmacol. 11:316–325. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pan S, Sun Y, Sui D, Yang T, Fu S, Wang J,
Hui B, Xi R, He C and Zhang X: Lobaplatin promotes
radiosensitivity, induces apoptosis, attenuates cancer stemness and
inhibits proliferation through PI3K/AKT pathway in esophageal
squamous cell carcinoma. Biomed Pharmacother. 102:567–574. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun X, Lou LG, Sui DH and Wu XH:
Preclinical activity of loba-platin as a single agent and in
combination with taxanes for ovarian carcinoma cells. Asian Pac J
Cancer Prev. 15:9939–9943. 2014. View Article : Google Scholar
|
|
33
|
Zhang CY, Bao W and Wang LH:
Downregulation of p16(ink4a) inhibits cell proliferation and
induces G1 cell cycle arrest in cervical cancer cells. Int J Mol
Med. 33:1577–1585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Korah J, Canaff L and Lebrun JJ: The
retinoblastoma tumor suppressor protein (pRb)/E2 promoter binding
factor 1 (E2F1) pathway as a novel mediator of TGFbeta induced
autophagy. J Biol Chem. 291:2043–2054. 2016. View Article : Google Scholar
|
|
35
|
Sheldon LA: Inhibition of E2F1 activity
and cell cycle progression by arsenic via retinoblastoma protein.
Cell Cycle. 16:2058–2072. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang Y and Peng XW: The silencing of long
non-coding RNA ANRIL suppresses invasion, and promotes apoptosis of
retino-blastoma cells through the ATM-E2F1 signaling pathway.
Biosci Rep. 38:BSR201805582018. View Article : Google Scholar
|
|
37
|
Dyson N: The regulation of E2F by
pRB-family proteins. Genes Dev. 12:2245–2262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kent LN, Bae S, Tsai SY, Tang X,
Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko
SM, et al: Dosage-dependent copy number gains in E2f1 and E2f3
drive hepatocellular carcinoma. J Clin Invest. 127:830–842. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Müller H, Bracken AP, Vernell R, Moroni
MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and
Helin K: E2Fs regulate the expression of genes involved in
differentiation, development, proliferation, and apoptosis. Genes
Dev. 15:267–285. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Poppy Roworth A, Ghari F and La Thangue
NB: To live or let die - complexity within the E2F1 pathway. Mol
Cell Oncol. 2:e9704802015. View Article : Google Scholar : PubMed/NCBI
|
